Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis

Fibrinolysis and Proteolysis

Volumn 11, Issue 3, 1997, Pages 121-128

  Mattsson, C ^a   Bjorkman J A ^a   Ulvinge, J C ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DESULFATOHIRUDIN; HEPARIN; MELAGATRAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CORONARY ARTERY THROMBOSIS; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; FIBRINOLYTIC THERAPY; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

EID: 0030663858     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80056-2     Document Type: Article

References (43)

1. TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. N Engl J Med 1985; 312: 932-936.
2. Collen D. Designing thrombolytic agents: focus on safety and efficacy. Am J Cardiol 1992; 69: 71-81A (443).
3. Bang NU, Wilhelm OG, Clayman MD. J Am Coll Cardiol 1989; 14: 837-849. (269).
4. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42 (269).
5. Schaer DH, Ross AM, Wasserman AG. Reinfarction, recurrent angina, and reocclusion after thrombolytic therapy. Circulation 1987; 76 (Suppl II):II-57-II-62 (263).
6. Gulba DC, Barthels M, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel W, Hecker H, Lichtlen. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction - relevance for the success of therapy. Circulation 1991; 83: 937-944 (273).
7. Ofusu F, Agnelli G, Hirsh J. New thrombin inhibitors: mode of action, experimental findings and clinical potential. Recent Adv Haematol 1992; 6: 45-72.
8. Hennekens CH, Buring JE, Sandercock P, et al. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular desease. Circulation 1989; 80: 749-756 (275).
9. GISSI Investigators. Long-term effects of intravenous thrombolyss in acute myocardial infarction: final report of the GISSI study. Lancet 1987; 2: 871-874.
10. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412-1417.
11. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433-1437.
12. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76: 145-154.
13. Johns JA, Gold HK, Leinbach RC, et al. Prevention of coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant tissue-type plasminogen activator. Circulation 1988; 78: 546-556.
14. Topol EJ, Georg BS, Kereiakes DJ, et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281-286.
15. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42.
16. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391.
17. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin II: implications for heparin therapy. Proc Natl Acad Sci USA 1989; 86: 3619-3923.
18. Maraganore JM. Hirudin and hirulog: Advances in antithrombotic therapy. Perspectives in drug discovery and design 1993; 1: 461-478.
19. Gusto IIb Investigators. A comparision of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Eng J Med 1966; 335: 775-781.
20. Chen L, Nichols WW, Mattsson C, Gustavsson D, Saldeen TGP, Metha JL. The low molecular weight thrombin inhibitor melagatran delays formation of electrically-induced occlusive thrombus in the canine coronary artery after oral administration. (Submitted).
21. Blair E, Nygren E, Cowley RA. A spiral wire technique for producing gradually occlusive coronary thrombosis. J Thorac Cardiovasc 1964: 48: 476-485.
22. Cercek B, Lew AS, Hod H, Yano J, Reddy J, Reddy NKN, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Am J Heart 1986; 74: 583-587.
23. Bergmann SR, Fox KAA, Ter-Pogossian MM, Sobel BE, Collen D. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science 1983; 220: 1181-1183.
24. Noren I, Ramström G, Wallen P. Fibrin plate method with reagents purified by affinity chromatography and its use for determination of fibrinolytic and other proteolytic activity in saliva, bile and plasma. Haemostasis 1975: 4: 110-124.
25. Reid TJ, Alving BM. A quantitative thrombin time for determining levels of hirudin and hirulog. Thromb Haem 1993; 70: 608-616.
26. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83: 1048-1056.
27. Lynch JJ, Sitko GR, Mellott M, Nutt EM, Lehman ED, Friedman PA, Dunwiddie T, Vlasuk GP. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparision of factor Xa versus thrombin inhibition. Card Res 1994; 28: 78-85.
28. Rote WE, Dun-Xue Mu, Bates ER, Nedelman MA, Lucchesi BR. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-Hirudin. J Cardiol Pharm. 1994; 23: 203-211.
29. Prager NA, Torr-Brown SR, Sobel BE, Abendschein DR. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. J Am Coll Cardiol 1993; 22: 296-301.
30. Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994; 89: 1802-1809.
31. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjuntive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor
32. Xa inhibitor, tic anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombolysis. Circulation 1992; 85: 805-815.
33. Jackson CV, Wilson HC, Growe VG, Shuman RT, Gesellchen PD. Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis:A comparision with heparin in a canine model of coronary artery thrombosis. J Card Pharm 1993; 21: 587-594.
34. Chen L, Nichols WW, Mattsson C, Teger-Nilsson AC, Saldeen TCP, Metha JL. Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. JPET 1996; 277: 1276-1282.
35. Gustafsson D, Antonsson T, Bylund R, Deinum J, Elg M, Eriksson U, Gyzander E, Karlsson O, Nilsson I, Mattsson C, Persson S, Sörensen S. Melagatran, a new low molecular weight thrombin inhibitor. Effects on thrombin and fibrinolytic enzymes. (Submitted to Thromb Haemost)
36. Markwardt F. Hirudin: The promising antithrombotic. Cardiovascular Drug Research 1992; 10: 211-232.
37. Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246: 355-357.
38. Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. (Submitted to Thromb Haemost)
39. May RD, Hawkeswood E, Powling MJ. Superior efficacy of low molecular weight thrombin inhibitors in a novel in vitro model of clot bound thrombin. Blood 1994; 84 (Suppl 1): 71a.
40. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparision with heparin and recombinant hirudin. Thromb Haem 1994; 72: 381-386.
41. Gast A, Tschopp TB, Schmid G, Hilpert K, Ackermann J. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagulation and Fibrinolysis 1994; 5: 879-887.
42. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-2100.
43. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation 1996; 93: 1328-1330.